Lunesta and Restless Leg Syndrome: Side Effects and Management
Lunesta (eszopiclone) does not cause restless leg syndrome as a side effect according to the FDA label, and if RLS symptoms develop while taking Lunesta, you should discontinue the medication and treat the RLS according to current guidelines. 1
Understanding the Relationship
The FDA-approved labeling for Lunesta does not list restless leg syndrome among its side effects 1. The documented side effects include:
- Most common: Unpleasant taste, dry mouth, drowsiness, dizziness, headache, cold symptoms
- Serious: Complex sleep behaviors (sleep-driving, sleep-walking), abnormal thoughts and behavior, memory loss, anxiety, severe allergic reactions
While some medications (particularly antipsychotics, antidepressants, and antiepileptics) can induce RLS 2, eszopiclone is not documented as a causative agent.
Clinical Approach
If RLS Develops While on Lunesta:
1. Evaluate the temporal relationship: Did RLS symptoms begin after starting Lunesta? This is unlikely to be causal but warrants investigation.
2. Consider discontinuation: If there's temporal correlation, stop Lunesta and observe for symptom resolution. The FDA label shows no serious withdrawal syndrome, though 2% or fewer patients may experience anxiety, abnormal dreams, nausea within 48 hours 1.
3. Treat the RLS directly using the 2025 AASM guidelines:
Evidence-Based RLS Treatment Algorithm
First-Line Treatments (Strong Recommendations):
Start with one of these three options 3:
- Gabapentin enacarbil (strong recommendation, moderate certainty)
- Gabapentin (strong recommendation, moderate certainty)
- Pregabalin (strong recommendation, moderate certainty)
Or consider IV iron therapy if appropriate iron parameters are met 3:
- IV ferric carboxymaltose (strong recommendation, moderate certainty)
Second-Line Options (Conditional Recommendations):
If first-line agents fail or are contraindicated 3:
- Ferrous sulfate with vitamin C (conditional recommendation, moderate certainty) - check iron status first
- Extended-release oxycodone or other opioids (conditional recommendation, moderate certainty)
- Dipyridamole (conditional recommendation, low certainty)
Avoid Dopaminergic Agents as Standard Treatment:
The 2025 AASM guidelines now suggest against standard use of 3:
- Pramipexole (conditional recommendation against)
- Ropinirole (conditional recommendation against)
- Rotigotine (conditional recommendation against)
- Levodopa (conditional recommendation against)
Critical caveat: These may be used short-term in patients who prioritize immediate symptom relief over long-term augmentation risk, but this represents a major shift from older guidelines 4, 5.
Strongly Avoid:
- Clonazepam (conditional recommendation against) 3 - despite being a benzodiazepine like some sleep aids, evidence does not support its use 6
- Cabergoline (strong recommendation against due to cardiac valvulopathy risk) 3
Key Clinical Pitfalls
Augmentation risk: The older 2018 guideline noted that dopaminergic agents carry significant augmentation risk 4, 5, which is why the 2025 AASM guidelines have shifted away from recommending them as standard therapy [3-3].
Iron status matters: Always check ferritin and transferrin saturation before prescribing iron therapy. The guidelines reference specific iron parameters that should guide treatment decisions 3.
Don't confuse insomnia treatment with RLS treatment: Lunesta treats insomnia 7, 8, not RLS. If both conditions coexist, they require separate management strategies.